Stephen D. Griffin - 03 Jun 2026 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Reporting relationship: President and CEO, Director
Issuer ticker: ANIK
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:05:07 UTC
Prior SEC filing: 30 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen D. Griffin

Key filing fact

Stephen D. Griffin filed Form 4 for Anika Therapeutics, Inc. (ANIK) on 05 Jun 2026.

Key facts

This page summarizes Stephen D. Griffin's Form 4 filing for Anika Therapeutics, Inc. (ANIK).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 30 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001831125 Primary reporting owner

Griffin Stephen D.

Relationship: President and CEO, Director
Address: C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD
Signature: /s/ Stephen D. Griffin
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIK transaction

Common Stock

Options Exercise

Transaction value
Shares: +12,840
Change %: +35%
Price
Shares after: 49,742
Date: 03 Jun 2026
Ownership: Direct
Footnotes: F1, F2

ANIK transaction

Common Stock

Tax liability

Transaction value
Shares: -3,769
Change %: -7.6%
Price: $14.41^*
Shares after: 45,973
Date: 03 Jun 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANIK transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -12,840
Change %: -50%
Price: $0.000000^*
Shares after: 12,840
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,840
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.

Footnote F2

Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.

Footnote F3

Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026.

Footnote F4

On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award.